Essentia Biosciences
- Company typePrivate
- Founded2021
- HeadquartersHaidian, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Essentia Biosciences firmographics
Firmographics- Name
- Essentia Biosciences
- Website
- https://essentiabiosciences.com
- Company type
- Private
- Founded year
- 2021
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Essentia Biosciences industry classification
Industry- Product category
- Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
Keywords
Where Essentia Biosciences is headquartered
LocationHeadquarters
- HQ city
- Haidian
- HQ country
- China
- HQ region
- Asia
Markets served
Essentia Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Essentia Biosciences product offering
Product offeringCore offering
Essentia Biosciences is a biotechnology company that develops cells, gene technology drugs, and medical devices. The company is at an early R&D stage, with a headcount of 1–10 employees and no commercialized products evidenced in the available sources.
Differentiator
Problem solved
Functional benefit
Companies that use Essentia Biosciences
Customer profileIdeal customer profiles1 record
Essentia Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Essentia Biosciences partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights3 records
Essentia Biosciences competitors and assessment
Company assessmentBroad incumbents
- GenScript Biotech: Hong Kong-listed biotech with cell therapy, gene synthesis, and life science services businesses. Comparable in the gene technology and cell therapy space with broader scale and a more diversified offering than Essentia.
- Allogene Therapeutics: US-based clinical-stage cell therapy company developing allogeneic CAR-T therapies. Comparable as a cell therapy biotech, though at a much later stage and far larger scale than Essentia.
- Innovent Biologics: Hong Kong-listed Chinese biotech developing biologics and cell therapies. Comparable as a Chinese biologics/gene-based therapeutics company with broader pipeline scale, providing a regional benchmark.
- CRISPR Therapeutics: Swiss/US clinical-stage gene editing biotech developing CRISPR/Cas9-based therapies. Comparable as a gene technology therapeutics player, though at commercial scale with approved products.
Emerging players
- Editas Medicine: US-based clinical-stage gene editing company developing CRISPR-based therapies. Comparable as a gene technology drug peer at a similar therapeutic-development stage.
- BRL Medicine: China-based gene therapy company developing AAV-delivered therapies for rare diseases. Comparable as a Chinese gene technology therapeutics peer at a similar early-commercialization stage.
Direct peers
- CARsgen Therapeutics: China-based clinical-stage biotech developing CAR-T cell therapies for solid tumors and hematologic malignancies. Comparable as a Chinese cell therapy company targeting similar oncology indications with autologous engineered cell platforms.
- Gracell Biotechnologies: China-based clinical-stage cell therapy company developing allogeneic and autologous CAR-T therapies. Comparable as a Chinese gene-engineered cell therapy peer with similar investor profile and platform approach.
- JW Therapeutics: Shanghai-based clinical-stage cell therapy company developing CAR-T therapies for hematologic cancers. Directly comparable to Essentia as a Chinese biotech focused on cell-based therapeutics with similar early-stage positioning and Chinese investor backing.
Others
- Beijing Molecular Technology: Investor in both of Essentia's funding rounds and a Beijing-based biotech investor/incubator. Included as an ecosystem peer given repeated co-investment signals and likely adjacency to other portfolio biotechs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Essentia Biosciences social profiles
Digital presenceEssentia Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Essentia Biosciences leadership team
Management profileNumber of profiles
Essentia Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Essentia Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Essentia Biosciences
What does Essentia Biosciences do?
Essentia Biosciences is a biotechnology company that develops cells, gene technology drugs, and medical devices. The company is at an early R&D stage, with a headcount of 1–10 employees and no commercialized products evidenced in the available sources.
When was Essentia Biosciences founded?
Essentia Biosciences was founded in 2021. It employs 1 to 10 people.
Where is Essentia Biosciences based?
Essentia Biosciences is headquartered in Haidian, China, in the Asia region.
Who are Essentia Biosciences's main competitors?
Broad incumbents on record are GenScript Biotech, Allogene Therapeutics, Innovent Biologics and CRISPR Therapeutics. Emerging players are Editas Medicine and BRL Medicine. Direct peers are CARsgen Therapeutics, Gracell Biotechnologies and JW Therapeutics. Beijing Molecular Technology is listed as an others.
Does Essentia Biosciences have an API?
No public API is recorded for Essentia Biosciences.
What industry is Essentia Biosciences in?
Essentia Biosciences's product category is Biotechnology. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 8731.